Inventurus Knowledge Solutions Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Inventurus Knowledge Solutions Ltd filed with BSE on 29 Apr 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
IKS Health announced a definitive merger agreement to acquire NASDAQ-listed TruBridge, a system-of-record provider for rural and community hospitals, for an enterprise value of $557 million. Management described the deal as instantly EPS and PAT accretive at close, with combined trailing-twelve-month revenue of about $698 million and adjusted EBITDA of about $186 million. Management also outlined a four-year internal financial reference point, targeting roughly INR3,000 crores EBITDA and near-zero net debt by the end of FY30, while stressing this was not formal guidance.
Numbers mentioned
Enterprise value of transaction: $557 million
p. 9
“So IKS is buying TruBridge, which is listed on the NASDAQ, for an overall enterprise value of $557 million, which is about $427 million in equity value and then we inherit their debt of about $130 million.”
Sachin Gupta, page 9 of the filed PDF · View the filing
Total debt at closing: a little under $600 million
p. 9
“That will lead to a total debt of a little under $600 million for IKS at the time of closing”
Sachin Gupta, page 9 of the filed PDF · View the filing
Starting leverage ratio: a little over 3x EBITDA
p. 9
“And this puts our starting leverage at a little over 3x EBITDA, which traditionally speaking I would say is a bit more than I'd genuinely like.”
Sachin Gupta, page 9 of the filed PDF · View the filing
TruBridge revenue: $347 million (trailing 12 months CY2025)
p. 10
“trailing 12 months 2025 calendar year, which is also their fiscal year, $347 million in revenue, about $126 million of that comes from the EHR business and about $221 million comes from the RCM business.”
Sachin Gupta, page 10 of the filed PDF · View the filing
TruBridge adjusted EBITDA: $69 million (FY25)
p. 10
“Doing all that, they've been delivering an adjusted EBITDA of about $69 million in fiscal 25 and obviously the opportunity to continue to grow that.”
Sachin Gupta, page 10 of the filed PDF · View the filing
Combined revenue: $698 million (trailing 12 months CY2025)
p. 10
“the combined business, if you take trailing 12 months calendar 25, would be about $698 million in revenue and $159 million in EBITDA, but really $186 million in EBITDA when you adjust out a couple of items from TruBridge's $43 million EBITDA”
Sachin Gupta, page 10 of the filed PDF · View the filing
Estimated EPS accretion: about $5 million
p. 10
“it starts to instantly be accretive to the tune of about $5 million.”
Sachin Gupta, page 10 of the filed PDF · View the filing
IKS EBITDA: INR1,000 crores (trailing 12 months December 31, 2025)
p. 16
“we're about a INR1,000 crores EBITDA business with a net debt of about INR300 crores.”
Sachin Gupta, page 16 of the filed PDF · View the filing
IKS net debt: INR300 crores (trailing 12 months December 31, 2025)
p. 16
“we're about a INR1,000 crores EBITDA business with a net debt of about INR300 crores.”
Sachin Gupta, page 16 of the filed PDF · View the filing
10-year revenue CAGR: 28% (10-year trajectory)
p. 17
“we've actually delivered 28% revenue growth and 33% EBITDA CAGR.”
Sachin Gupta, page 17 of the filed PDF · View the filing
RCM TAM within rural hospitals: $3.5 to $4 billion
p. 11
“That itself comes to about a $3.5 to $4 billion RCM TAM within these rural hospitals.”
Sachin Gupta, page 11 of the filed PDF · View the filing
White space in TruBridge captive install base: $450 million
p. 11
“And TruBridge's RCM revenue is around $220 million, so it creates about $450 million of white space in their captive install base.”
Sachin Gupta, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA — INR3,000 crores · by end of FY30
stated as an aspiration by Sachin Gupta
p. 16
“we should be, in my -- and please, I want to caveat this again and again, this is not a guidance, and I know that even if I say that you guys will assume whatever it is, but this is our true north.”
Sachin Gupta, page 16 of the filed PDF · View the filing
Net debt — near zero / December 2025 levels · by end of FY30
stated as an aspiration by Sachin Gupta
p. 17
“if by the end of FY30 we've not delivered something in the range of a INR3,000 crores EBITDA and gotten our net debt levels back to -- the net debt levels that we were at in December 2025, which eventually is very close to zero in the larger context.”
Sachin Gupta, page 17 of the filed PDF · View the filing
Transaction close timeline — 90 to 120 days
stated firmly by Sachin Gupta
p. 17
“It's expected to take 90 to 120 days to close.”
Sachin Gupta, page 17 of the filed PDF · View the filing
Integration timeline post-close — 4 to 5 quarters · post-close
stated firmly by Sachin Gupta
p. 17
“Once the transaction closes, we anticipate a 4 to 5-year, four to five quarter integration process where we start combining ourselves into one company.”
Sachin Gupta, page 17 of the filed PDF · View the filing
Combined pro forma EBITDA margin — early 30s% · relatively rapidly
stated as an aspiration by Sachin Gupta
p. 22
“you're going to start off with 26% combined pro forma here and, you know, we feel like we'll be in the early 30s, you know, relatively rapidly.”
Sachin Gupta, page 22 of the filed PDF · View the filing
Growth in traditional physician group market — faster than 12% industry growth
stated firmly by Sachin Gupta
p. 26
“we are continuing to say we will want to continue to capture market share, which means we'll grow faster than the 12% that the industry is growing at.”
Sachin Gupta, page 26 of the filed PDF · View the filing
Synergy realization timeline — two and a half to three years
stated conditionally by Sachin Gupta
p. 21
“I feel like, you know, over a two and a half to three year period all the synergies should be fully tucked in.”
Sachin Gupta, page 21 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Sachin declined to give specifics, saying only that a four-year True North was provided and synergies would come from G&A and RCM delivery model transformation.
Answered by Sachin Gupta
Asked by Keyur Ladhawala: Can you quantify the synergies expected from the transaction?
p. 20
“I really would like to avoid going into the specifics of the journey from INR1,000 crores to INR3,000 crores in terms of what are the key drivers.”
Sachin Gupta, page 20 of the filed PDF · View the filing
Sachin said TruBridge had twice failed to globalize its RCM delivery model and struggled to invest in modernization, making a partner combination attractive.
Answered by Sachin Gupta
Asked by Aashray Vasa: Why did TruBridge decide to sell given its own performance struggles?
p. 21
“they have tried two attempts in the past at globalizing their RCM operations. And they have been less than successful at those two attempts.”
Sachin Gupta, page 21 of the filed PDF · View the filing
Nithya noted rural hospitals spend a much higher share of revenue on RCM than large systems, strengthening the outsourcing value proposition.
Answered by Nithya Balasubramanian
Asked by Vishnu Gopal: How does RCM management differ between larger hospital systems and rural hospital systems?
p. 24
“for a larger hospital system, because of the scale, what they end up spending on RCM is somewhere in the zip code of 4% to 5%. That's almost double in a rural community hospital.”
Nithya Balasubramanian, page 24 of the filed PDF · View the filing
Sachin outlined a phased approach: initial quarters for learning and regulatory limits, then G&A synergy capture, then operational transformation starting around Q3 post-close.
Answered by Sachin Gupta
Asked by Chirag Kachhadiya: What are the steps for integrating TruBridge's operations?
p. 25
“I would say Q1 post-close learning, Q2 actioning, start to combine into one organization structure, start to realize G&A, really start to understand the customer base, and perhaps towards the end of Q2, early Q3 post-close is when we start actioning the operational transformation.”
Sachin Gupta, page 25 of the filed PDF · View the filing
Sachin said he needs two-three quarters post-close to understand the rural healthcare growth trajectory, while reaffirming growth aspirations in the traditional physician segment.
Answered by Sachin Gupta
Asked by Abhishek Gupta: Are the growth aspirations for the combined business still being maintained?
p. 26
“I need two-three quarters to better understand this market once it closes to know what exactly the growth trajectory will look like in the rural healthcare market.”
Sachin Gupta, page 26 of the filed PDF · View the filing
Sachin said TruBridge lacked a successful globalized human-in-the-loop delivery model, which IKS could bring.
Answered by Sachin Gupta
Asked by Madhuchanda Dey: Why couldn't TruBridge, already a technology company, achieve these RCM improvements on its own?
p. 27
“the human-in-the-loop TruBridge in all candour has not been able to execute successfully from a globalized human-in-the-loop perspective, which IKS has the expertise around”
Sachin Gupta, page 27 of the filed PDF · View the filing
Sachin said the immediate captive EHR install base TAM is about $600 million, with a further $3-4 billion adjacent rural hospital RCM market.
Answered by Sachin Gupta
Asked by Chetan Shah: What is the size of the additional TAM created by this acquisition?
p. 28
“there's at least a $600 million opportunity in their EHR captive install base.”
Sachin Gupta, page 28 of the filed PDF · View the filing
Saransh explained that historical amortization was on a declining schedule and a new constant asset life figure would be created and validated by valuation experts.
Answered by Saransh Mundra
Asked by Vamshi Krishna: Why wasn't TruBridge's $12 million amortization impact from acquired intangibles included in the pro forma PAT accretion calculation?
p. 29
“while you see historically what the numbers were, it was on a declining trend. And what we've now put is sort of a constant number, and we can discuss that in more detail.”
Saransh Mundra, page 29 of the filed PDF · View the filing
Risks flagged
Starting leverage ratio is higher than management would ideally like
p. 9
“And this puts our starting leverage at a little over 3x EBITDA, which traditionally speaking I would say is a bit more than I'd genuinely like.”
Sachin Gupta, page 9 of the filed PDF · View the filing
Cross-sell execution in a large acquisition previously took longer than expected
p. 11
“It's a simple cross-sell of, you know, the other thing that, you know, you might recall is but we had also thought of doing cross-sell in the Acuity deal, it took longer than expected.”
Sachin Gupta, page 11 of the filed PDF · View the filing
Potential price compression in RCM take rates due to AI-based automation
p. 11
“we believe that as we ourselves build agentic AI-based orchestration of tasks that can be orchestrated autonomously or even with some human in the loop, there will be some price compression, so we took a very, very conservative number.”
Sachin Gupta, page 11 of the filed PDF · View the filing
TruBridge has twice failed at globalizing its RCM operations
p. 21
“they have tried two attempts in the past at globalizing their RCM operations. And they have been less than successful at those two attempts.”
Sachin Gupta, page 21 of the filed PDF · View the filing
Regulatory approval process, including FTC review, could affect deal timing
p. 17
“work through the regulatory approval process, which includes the HSR approval from the FTC, which is the Federal Trade Commission.”
Sachin Gupta, page 17 of the filed PDF · View the filing
Uncertainty in short-term integration, including possible learnings and mistakes
p. 20
“we factored in a certain amount of uncertainty in the short term, learnings in the short term, mistakes perhaps new mistakes, hopefully not the same mistakes in the short term.”
Sachin Gupta, page 20 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.